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ORIGINAL INVESTIGATION
Empagliflozin lessened cardiac injury 
and reduced visceral adipocyte hypertrophy 
in prediabetic rats with metabolic syndrome
Hiroaki Kusaka1, Nobutaka Koibuchi1, Yu Hasegawa1, Hisao Ogawa2 and Shokei Kim‑Mitsuyama1*
Abstract 
Background: The potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. 
This work was undertaken to investigate the non‑glycemic effect of empagliflozin on metabolic syndrome rats with 
prediabetes.
Methods: SHR/NDmcr‑cp(+/+) rats (SHRcp), a model of metabolic syndrome with prediabetes, were given empagli‑
flozin for 10 weeks to examine the effects on urinary sodium and water balance, visceral and subcutaneous adipocyte, 
and cardiac injury. Further, the effect of empagliflozin on blood pressure and autonomic nervous system was continu‑
ously investigated by using radiotelemetry system.
Results: Empagliflozin significantly reduced urinary sodium and water balance of SHRcp only within 1 week of the 
treatment, but later than 1 week did not alter them throughout the treatment. Empagliflozin significantly reduced 
body weight of SHRcp, which was mainly attributed to the significant reduction of subcutaneous fat mass. Empa‑
gliflozin significantly reduced the size of visceral adipocytes and increased the number of smaller size of adipocytes, 
which was associated with the attenuation of oxidative stress. Empagliflozin ameliorated cardiac hypertrophy and 
fibrosis of SHRcp, in association with the attenuation of cardiac oxidative stress and inflammation. However, empa‑
gliflozin did not significantly change blood pressure, heart rate, sympathetic activity, or baroreceptor function, as 
evidenced by radiotelemetry analysis.
Conclusions: Our present work provided the evidence that SGLT2 inhibition reduced visceral adipocytes hypertro‑
phy and ameliorated cardiac injury in prediabetic metabolic syndrome rat, independently of diuretic effect or blood 
pressure lowering effect. Thus, SGLT2 inhibition seems to be a promising therapeutic strategy for prediabetic meta‑
bolic syndrome.
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Background
Type 2 diabetes is a major risk factor for cardiovascular 
disease [1, 2]. However, there is no convincing evidence 
that glucose-lowering therapy significantly reduces 
the rates of cardiovascular events and death, namely, 
macrovascular complications [3–9]. Sodium-glucose 
cotransporter 2 inhibitors [10, 11] are novel class of anti-
hyperglycemic medications which increase urinary glu-
cose excretion and thereby improving glycemic control 
independent of insulin. Recently, the EMPA-REG OUT-
COME trial [12–14], which examined the effect of empa-
gliflozin, a sodium glucose-cotransporter 2 inhibitor, in 
addition to standard therapy on cardiovascular morbidity 
and mortality in patients with type 2 diabetes at high risk, 
provided the findings that compared to placebo, empagli-
flozin significantly reduced the combined cardiovascular 
endpoint, cardiovascular death, overall mortality, and 
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heart failure hospitalization. Thus, empagliflozin treat-
ment shows the significant benefit in improving cardio-
vascular prognosis in high risk type 2 diabetic patients. 
However, the mechanism(s) underlying the reduction of 
cardiovascular events by empagliflozin reported in this 
trial remain to be elucidated. The potential non-glycemic 
benefit of SGLT2 inhibition has been paid the most atten-
tion since the reports of EMPA-REG OUTCOME trial.
Although SGLT2 inhibitors are shown to exert not only 
antihyperglycemic effect but also non-glycemic effects 
such as natriuresis, body weight reduction, blood pres-
sure-lowering effect, or lipid-lowering effect, the pre-
vious reports regarding these non-glycemic effects of 
SGLT2 inhibitors are limited to diabetic animals [15–20] 
or patients [21–26]. The effect of SGLT2 inhibition on 
prediabetic metabolic syndrome is unknown. Therefore, 
to address this issue, in the present study, we investigated 
the effect of empagliflozin in a rat model of metabolic 




All procedures were performed in accordance with the 
institutional guidelines for animal research and were 
approved by the Animal Care and Use Committee of 
Kumamoto University.
Experimental animals
Male SHR/NDmcr-cp(+/+) rats (SHRcp) [27–29], a 
rat model of metabolic syndrome characterized by obe-
sity, insulin resistance, impaired glucose tolerance with 
normal fasting blood glucose, hypertension, and hyper-
lipidemia, were purchased from Japan SLC (Shizuoka, 
Japan). The rats were housed in an animal facility with a 
12 h light–dark cycle and were given water ad libitum.
Drugs
Empagliflozin, a selective sodium-glucose cotrans-
porter-2 (SGLT2) inhibitor, was kindly supplied by 
Boehringer Ingelheim Pharma GmbH & Co. (KG, 
Germany).
Study protocol
The present study consisted of three experiments as 
described below.
Experiment I
This experiment was performed for metabolic cage anal-
ysis (see Additional file 1: Figure S1a). Twenty-week-old 
SHRcp were divided into two groups and were given 
(1) the standard diet (MF diet, ORIENTAL YEAST Co., 
Ltd, Tokyo, Japan) and (2) the standard diet containing 
0.03% empagliflozin. Drug treatment was carried out for 
10 weeks. During the first week (7 days), individual rats 
were housed in a metabolic cage (Techniplast 3701M001, 
Buguggiate, Italy) to collect 24-h urinary samples every 
day, and thereafter the animals were housed in a meta-
bolic cage once a week for collection of 24-h urinary 
samples (see Additional file  1: Figure S1A). Urine vol-
ume, urinary excretions of glucose, Na and creatinine, 
food intake, and water intake were determined per 24 h 
in individual rats, and 24-h sodium or water balance, and 
cumulative 24-h sodium or water balance were calcu-
lated, as described below.
Experiment II
This experiment was performed to investigate the effect 
of long-term empagliflozin treatment on cardiac and 
fat tissues in SHRcp (see Additional file  1: Figure S1B). 
Twenty-two-week-old SHRcp rats were divided into 
two groups and were given (1) the standard diet or (2) 
the standard diet containing 0.03% empagliflozin for 
10  weeks in the same manner as Experiment I. After 
10 weeks of treatment, under anesthesia with isoflurane, 
blood was collected by cardiac puncture, and the heart, 
subcutaneous fat, epididymal fat, and liver were rapidly 
excised from each rat to examine the effects of empa-
gliflozin on various parameters of cardiac tissue and fat 
tissue as described below. According to our previous 
report [27] on the detailed characteristics of SHRcp com-
pared to control WKY, the slight difference in study age 
between Experiments I and II seems to be negligible.
Experiment III
This experiment was performed to continuously moni-
tor the effect of empagliflozin on arterial blood pressure 
(BP) and heart rate (HR) of SHRcp, using radiotelem-
etry system (Data Science International, St Paul, MN, 
USA) (see Additional file 1: Figure S1C). The detail of our 
methods has been previously reported and the validity of 
our method has been well established [27, 30]. We used 
younger (12 to 13-week-old) SHRcp which has much 
less visceral fat than 20 to 22-week-old SHRcp, because 
older SHRcp has highly large amount of visceral fat tis-
sue which hampers us to successfully implant telemetry 
device in older SHRcp. In brief, the tip of the transmitter 
catheter was inserted into the abdominal aorta of 12 to 
13-week-old SHRcp and the transmitter was sutured to 
the ventral wall of the abdominal cavity. BP and HR were 
continuously recorded using a computer system (DATA-
QUEST ART4.2 Acquisition; Data Sciences International, 
St Paul, MN, USA). After recovery period, 15-week-old 
SHRcp were divided into two groups and were given 
(1) the standard diet or (2) the standard diet containing 
0.03% empagliflozin for 7 weeks. The data were recorded 
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with 30-s averages every 5 min for BP, HR and locomotor 
activity and with a 5-min average every 60 min. Sponta-
neous baroreceptor reflex gain (sBRG) was determined 
from spontaneous changes in systolic BP and pulse inter-
val (PI) using a modified time-series method established 
by Oosting et al. and Waki et al. [30–33].
HR and systolic BP variability (low frequency (LF)/high 
frequency (HF) ratio of PI and LF of systolic BP) were 
calculated using data-analysis program contained a fast 
Fourier transform function for power spectral analysis 
established by Oosting et al. and Waki H et al. [30–33].
Calculation of 24‑h sodium balance, cumulative sodium 
balance, 24‑h water balance, and cumulative water balance 
in Experiment I
In the above mentioned Experiment I, 24-h sodium 
intake was calculated by multiplying food intake (g) by 
the diet sodium content (0.19% NaCl  =  0.082  mmol 
Na+/g food). Twenty-four-hour sodium excretion was 
calculated by multiplying the 24-h urine volume (mL) 
and urinary sodium concentration (mmol Na+/mL). 
Twenty-four-hour sodium balance was calculated as 24-h 
sodium intake minus 24-h sodium excretion. Twenty-
four-hour water balance was calculated as 24-h water 
intake minus 24-h urine volume. Cumulative sodium or 
water balance was calculated from sequential summation 
of daily balances according to our previous report [34].
Histological analysis and immunohistochemistry of the 
heart
To evaluate cardiac interstitial fibrosis, hearts were fixed 
with 4% formalin overnight, embedded in paraffin, cut 
into 4-μm thick coronal sections, and stained with Sirius 
Red F3BA (0.5% in saturated aqueous picric acid, Aldrich 
Chemical Company, Milwaukee, WI, USA). Positive 
fibrosis area per field area was assessed by examining at 
least 10 fields per rat using WinRoof Version 5.8 (Mitani 
Corporation, Fukui, Japan).
To evaluate cardiac interstitial macrophage infiltration, 
hearts were fixed with 4% formalin overnight, embed-
ded in paraffin, cut into 4-μm thick coronal sections, and 
immunostained with anti-ED-1 antibodies (BMA Bio-
medicals, Augst, Switzerland) (working dilution 1:500) 
to identify monocytes/macrophages, as described previ-
ously [35]. The number of cardiac ED-1 positive cells per 
field area (mm2) was counted by examining more than 
ten fields per section using a microscope with 200× mag-
nification; the average number of ED-1 positive cells was 
obtained for each rat.
To evaluate cardiomyocyte size [36], cardiac tissue 
were fixed with 4% formalin overnight, embedded in par-
affin, cut into 4-μm thick coronal sections, and stained 
with fluorescein-tagged wheat germ agglutinin (FITC-
WGA, Sigma-Aldrich, St. Louis, MO). Minimal Feret’s 
diameter of cardiomyocyte was assessed by examining 
at least 100 cell sizes per rat using WinRoof Version 5.8 
(Mitani Corporation, Fukui).
Measurement of cardiac superoxide
Dihydroethidium (DHE) was used to evaluate tissue 
superoxide levels in  situ, as described previously [27]. 
DHE fluorescence of cardiac sections was quantified 
using WinRoof Version 5.8 (Mitani Corporation, Fukui). 
The mean fluorescence was quantified and expressed rel-
ative to values obtained from control rats.
Measurement of triglyceride in left ventricular tissue
Triglyceride in left ventricular tissue was measured 
with a commercial assay kit (Bio Vision, Inc., CA, USA) 
according to the manufacturer’s recommended protocol.
Measurement of adipocyte size and adiponectin 
in epididymal and subcutaneous adipose tissue
To evaluate adipocyte size, epididymal (visceral) and 
subcutaneous adipose tissue were fixed with 4% forma-
lin overnight, embedded in paraffin, cut into 4-μm thick 
coronal sections, and stained with haematoxylin and 
eosin. Adipocyte size was assessed by examining at least 
100 cell sizes per rat using WinRoof Version 5.8 (Mitani 
Corporation, Fukui).
Adiponectin protein levels in adipose tissues were ana-
lyzed using a mouse/rat adiponectin ELISA kit (Otsuka 
Pharmaceutical, Tokyo, Japan). Protein extraction from 
adipose tissue and protein quantification were performed 
as described by other investigators [37].
Measurement of thiobarbituric acid reactive substrances 
(TBARS)
Lipid oxidation was evaluated by measuring the amounts 
of malondialdehyde (MDA) produced thiobarbituric acid 
reactive substances (TBARS), using a commercial assay 
kit (Cayman Chemical, Ann Arbor). Briefly, adipose tis-
sue homogenate, sodium dodecyl sulphate, acetic acid 
and TBA were mixed. The mixtures were heated at 95 °C 
in a water bath for 60  min. After incubation the tubes 
were cooled to room temperature the upper organic layer 
was taken and its OD read at 532 nm against an appropri-
ate blank without the sample.
Measurement of urinary and blood variables
Serum total cholesterol, triglyceride, and free fatty acid, 
and urinary electrolytes were measured at SRL, Inc. 
(Tokyo, Japan). Measurement of HbA1C was performed 
at biopathological medicine (Kanagawa, Japan). Plasma 
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insulin was measured with a kit (Morinaga Institute of 
Biological Science, Inc, Yokohama).
Statistical analysis
All of the data are presented as mean ± SEM. The differ-
ence among comparison groups was tested with appro-
priate statistical method, as shown in each Figure legend 
and tables. P < 0.05 was considered significant. Statistical 
analyses were performed using GraphPad Prism version 
6.0 for Windows (GraphPad Software, San Diego, CA).
Results
The effects of short‑term (7 days) empagliflozin treatment 
on daily body weight, food intake, water intake, urine 
volume, urinary glucose and sodium excretions, and water 
and sodium balances in SHRcp
There was no significant difference in daily body weight and 
daily food intake between control and empagliflozin groups 
during 7 days of the treatment (Fig. 1a, b), but there was a 
significant interaction (P < 0.01) regarding daily food intake 
(Table 1). However, compared with control group, empagli-
flozin significantly increased daily water intake, urine vol-
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Fig. 1 Effect of short‑term (7 days) empagliflozin treatment on various parameters (a–f) obtained from daily metabolic cage analysis of SHRcp. 
Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are 
mean ± SEM n = 6 in control, n = 5 in SGLT2. Statistical analysis was performed by two‑factor ANOVA with repeated measures followed by post 
hoc Bonferroni’s multiple comparisons test. #P < 0.05, *P < 0.01 versus control
Table 1 Main effects and  interaction P values for  drug 
and time analyzed by two-way ANOVA in Experiment I
UGE urinary glucose excretion; NS not significant
Parameters (figure number) Ptime Pdrug Pinteraction
Body weight (Fig. 1a) <0.01 NS NS
24 h‑food intake (Fig. 1b) <0.01 NS <0.01
24 h‑water intake (Fig. 1c) <0.01 <0.01 <0.01
24 h‑urine volume (Fig. 1d) <0.01 <0.01 <0.01
24 h‑UGE (Fig. 1e) <0.01 <0.01 <0.01
24 h‑urinary sodium excretion (Fig. 1f ) <0.01 <0.01 <0.01
24 h‑sodium balance (Fig. 2a) <0.01 <0.01 <0.01
Cumulative 24 h‑sodium balance (Fig. 2b) <0.01 <0.01 <0.01
24 h‑water balance (Fig. 2c) <0.01 <0.05 0.6951
Cumulative 24 h‑water balance (Fig. 2d) <0.01 <0.05 <0.01
Body weight (Fig. 3a) <0.01 <0.05 <0.01
24 h‑food intake (Fig. 3b) <0.01 <0.01 <0.01
24 h‑water intake (Fig. 3c) <0.01 <0.01 <0.01
24 h‑urine volume (Fig. 3d) <0.01 <0.01 <0.01
24 h‑UGE (Fig. 3e) <0.01 <0.01 <0.01
24 h‑urinary sodium excretion (Fig. 3f ) <0.01 NS <0.01
24 h‑sodium balance (Fig. 3g) <0.01 NS NS
24 h‑water balance (Fig. 3h) <0.01 NS <0.01
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Furthermore, 24-h urinary sodium excretions were larger 
in empagliflozin group than those in control group (Fig. 1f), 
and there was a significant interaction (P  <  0.01) regard-
ing 24-h urinary sodium excretion (Table  1). As shown 
in Fig.  2, relative to control, empagliflozin significantly 
decreased daily sodium balance and cumulative 24-h 
sodium balance, and significantly reduced cumulative 24-h 
water balance within 7 days of the treatment.
The effect of long‑term (10 weeks) empagliflozin treatment 
on body weight, food intake, water intake, urine volume, 
urinary glucose and sodium excretions, and water 
and sodium balances in SHRcp
Body weight began to be significantly less in empagliflo-
zin group than in control group from 7 weeks after initia-
tion of empagliflozin treatment (Fig. 3a), while 24-h food 
intake began to be significantly greater in empagliflozin 
group than in control group from 5  weeks (Fig.  3b). As 
with the above mentioned short-term effects of empa-
gliflozin treatment, 24-h water intake, urine volume, and 
urinary glucose excretions continued to be greater in 
empagliflozin group than in control group from 1  week 
until 10 weeks of the treatment (Fig. 3c, d, e).
Different from the shot-term (7 days) effects of empa-
gliflozin, there was no significant difference in 24-h 
urinary sodium excretion, sodium balance, and water 
balance between empagliflozin and control group until 
the end of the treatment (10 weeks) (Fig. 3f, g, h). How-
ever, there was a significant interaction (P < 0.01) regard-
ing 24-h water balance (Table 1).
The effects of empagliflozin treatment on organ weight 
in SHRcp
After 10  weeks of the treatment, body weight was sig-
nificantly less in empagliflozin group versus control 
group (664.2 ± 9.2 versus 733.3 ± 5.3 g; P < 0.01), while 
tibia length was similar between the groups (Table  2). 
There was no significant difference between the empa-
gliflozin and control groups regarding the weight of 
visceral fat tissues including epididymal fat (7.0  ±  0.3 
versus 6.4  ±  0.2  g), mesenteric fat (11.8  ±  0.2 ver-
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Fig. 2 Effect of short‑term (7 days) empagliflozin treatment on daily 24‑h sodium balance (a), cumulative 24‑h sodium balance (b), 24‑h water 
balance (c), and cumulative 24‑h water balance (d) of SHRcp. Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; 
UGE urinary glucose excretion; NS not significant. Values are mean ± SEM n = 6 in control, n = 5 in SGLT2. Statistical analysis was performed by two‑
factor ANOVA with repeated measures followed by post hoc Bonferroni’s multiple comparisons test. #P < 0.05, *P < 0.01 versus control
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56.2 ± 1.0 g) (Table 2). On the other hand, subcutaneous 
fat weight was significantly less in empagliflozin group 
versus control group (52.7  ±  2.2 versus 69.0  ±  1.5  g; 
P < 0.01), (Table 2). There was no significant difference in 
liver weight (Table 2).
Left ventricular weight was significantly less in empa-
gliflozin group versus control group (1363  ±  16 versus 
1465 ± 44 mg; P < 0.05) (Table 2).
The effects of empagliflozin treatment on adipocyte size 
distribution in visceral and subcutaneous adipose tissues
Figure  4 indicates morphological analysis of epididy-
mal (visceral) fat and subcutaneous fat tissues. In both 
epididymal (P  <  0.01) and subcutaneous (P  <  0.01) fat 
tissues, mean adipocyte size in empagliflozin group was 
significantly smaller than that in control group (Fig. 4a, b, 
respectively). Furthermore, in both epididymal and sub-
cutaneous fat tissue, empagliflozin group had higher pro-
portion of small size of adipocytes and lower proportion 
of large size of adipocytes than control group (Fig. 4c, d, 
respectively).
Effect of empagliflozin treatment on adiponectin 
and oxidative stress of adipose tissue
There is no significant difference between the control 
and empagliflozin groups regarding epididymal fat adi-
ponectin (1.16 ± 0.07 versus 1.03 ± 0.08 ng/μg protein) 
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Fig. 3 Effect of long‑term (10 weeks) empagliflozin treatment on various parameters (a–h) obtained from weekly metabolic cage analysis. Control 
SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are 
mean ± SEM n = 6 in control, n = 6 in SGLT2. Statistical analysis was performed by two‑factor ANOVA with repeated measures followed by post 
hoc Bonferroni’s multiple comparisons test
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As shown in Fig.  5, epididymal fat TBARS (lipid oxi-
dation) levels were less in empagliflozin group than in 
control group (P  <  0.05), while there was no significant 
difference between the two groups regarding subcutane-
ous fat TBARS.
Effect of empagliflozin treatment on cardiac injury 
of SHRcp
As described above (Table 2), left ventricular weight was 
significantly less in empagliflozin group than in control 
group. Therefore, we performed histological analysis of 
cardiac tissue in SHRcp. As shown in Fig. 6a, empagliflo-
zin significantly reduced minimal Feret’s diameter of car-
diomyocyte in SHRcp (P < 0.05). Moreover, empagliflozin 
ameliorated cardiac interstitial fibrosis (P < 0.01), super-
oxide levels (P < 0.01), and ED-1-positive cell infiltration 
(P  <  0.01) in SHRcp (Fig.  6b, c, d). Cardiac triglyceride 
Table 2 Effect of long-term (10 weeks) empagliflozin treat-
ment on  body weight, tibia length, visceral fat weight, 
subcutaneous fat weight, liver weight, and left ventricular 
weight of SHRcp
Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing 
empagliflozin. Values are mean ± SEM. Statistical analysis was performed by 
unpaired Student’s t test
#  P < 0.05, * P < 0.01 versus control
Control (n = 12) SGLT2 (n = 12)
Body weight (g) 733.3 ± 5.3 664.0 ± 9.2*
Tibia length (mm) 39.1 ± 0.1 39.0 ± 0.1
Epididymal fat weight (g) 6.4 ± 0.2 7.0 ± 0.3
Mesenteric fat weight (g) 12.3 ± 0.2 11.8 ± 0.2
Perirenal fat weight (g) 56.2 ± 1.0 53.8 ± 1.3
Subcutaneous fat weight (g) 69.0 ± 1.5 52.7 ± 2.2*
Liver weight (g) 29.5 ± 0.74 28.6 ± 0.35





































































































Fig. 4 Effect of long‑term (10 weeks) empagliflozin treatment on epididymal adipocyte size (a, c) and subcutaneous adipocyte size (b, d) of SHRcp. 
Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are 
mean ± SEM n = 9 in control, n = 9 in SGLT2. In a and b, statistical analysis was performed by unpaired Student’s t test. In c and d, statistical analy‑
sis was performed by two‑factor ANOVA with repeated measures followed by post hoc uncorrected Fisher’s LSD multiple comparisons test
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Fig. 5 Effect of long‑term (10 weeks) empagliflozin treatment on epididymal (a) and subcutaneous (b) fat tissue TBARS of SHRcp. Control SHRcp 
fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are mean ± SEM 





























































































Fig. 6 Effect of long‑term (10 weeks) empagliflozin treatment on cardiomyocyte minimal Feret’s diameter (a), cardiac interstitial fibrosis (b), cardiac 
DHE fluorescence (c), cardiac ED‑1‑positive cell numbers (d), and cardiac triglyceride contents (e) of SHRcp. Control SHRcp fed control diet; SGLT2, 
SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not significant. Values are mean ± SEM n = 12 in control, n = 12 
in SGLT2. Statistical analysis was performed by unpaired Student’s t test
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levels were not significantly different between the two 
groups (Fig. 6e).
The effects of empagliflozin treatment on serum 
biochemical parameters in SHRcp
As shown in Table  3, after 10  weeks of the treatment, 
empagliflozin significantly decreased non-fasting blood 
glucose (P  <  0.01), HbA1c (P  <  0.01) and serum insulin 
(P  <  0.01) than control, but did not change serum total 
cholesterol and free fatty acid, and increased triglyceride 
levels (P < 0.01) than control.
Effects of empagliflozin treatment on blood pressure, heart 
rate, and locomotor activity in SHRcp
Blood pressure and heart rate were continuously moni-
tored in SHRcp for 7  weeks by using telemetry system. 
As shown in Fig.  7, there was no significant difference 
between empagliflozin and control groups throughout 
the treatment, regarding 24-h-averaged systolic BP and 
diastolic BP (Fig.  7a), 24-h-averaged HR (Fig.  7b), or 
24-h-averaged locomotor activity (Fig. 7c). Furthermore, 
as shown by circadian rhythm hourly recorded during 
24 h (12-h dark period and 12-h light period) in Fig. 7d–
g, there was no significant difference between empagliflo-
zin and control groups regarding systolic BP, diastolic BP, 
HR, or locomotor activity during 12-h dark period and 
12-h light period (Table 4). 
Effects of empagliflozin treatment on autonomic function 
in SHRcp
Figure 8 indicates hourly LF-SBP, sBRG, and LF/HF ratio 
of PI in each group of SHRcp rats on 45  day after start 
of drug treatment. Compared with control, empagliflozin 
treatment did not alter LF-SBP, sBRG, and LF/HF ratio of 
PI during 24 h (12-h dark period and 12-h light period) 
in SHRcp.
Discussion
At present, available data regarding the effect of SGLT2 
inhibition on MS with prediabetic stage is very scarce. 
The major findings of our present work were as fol-
lows: (1) empagliflozin significantly ameliorated car-
diac hypertrophy and interstitial fibrosis in association 
with the attenuation of cardiac oxidative stress and 
inflammation in prediabetic MS rat, independently of 
blood pressure and lipid metabolism; (2) empagliflozin 
reduced visceral adipocyte hypertrophy in prediabetic 
MS rats. These results provided the first evidence sug-
gesting that SGLT2 inhibition with empagliflozin may 
provide the therapeutic benefit in MS with prediabetic 
stage.
Recently, EMPA-REG OUTCOME trial provides the 
evidence that SGLT2 inhibition with empagliflozin sig-
nificantly reduces cardiovascular events and heart fail-
ure hospitalization in type 2 diabetic patients at high risk 
[12–14, 38]. However, the underlying mechanism for the 
benefit of empagliflozin in cardiovascular risk reduction 
remains to be determined. Interestingly, SGLT2 inhibi-
tors including empagliflozin exert non-glycemic effect 
in type 2 diabetic patients [11, 21, 24–26] or animal 
models [16, 17, 19, 39], such as reduction in blood pres-
sure, decrease in body weight, or natriuresis. Therefore, 
SGLT2 inhibition is proposed to provide cardiovascular 
protection partially independently of blood glucose con-
trol. However, the investigation on the effect of SGLT2 
inhibition is limited to type 2 diabetic humans and ani-
mals, and its effect on prediabetic MS is unknown. These 
findings encouraged us to investigate the effect of empa-
gliflozin on prediabetic MS rat model. In our previous 
paper, we have characterized in detail the phenotype of 
SHRcp compared to genetic control Wistar-Kyoto rats 
(WKY) [27]. We showed that compared to control WKY 
rat, SHRcp exhibited visceral obesity, insulin resistance, 
impaired glucose tolerance with fasting normoglyce-
mia, hypertension, and hyperlipidemia, thereby indicat-
ing that SHRcp is a useful model of MS with prediabetic 
stage [27].
Clinical studies showed that empagliflozin monother-
apy reduced postprandial glucose from the first day and 
improved 24-h glucose variability in Japanese patients 
with type 2 diabetes [40], the combination of empagli-
flozin with metformin significantly reduced HbA1c with 
good tolerability in type 2 diabetic patients [41], and 
long-term empagliflozin monotherapy in drug-naive 
patients with type 2 diabetes led to sustained reductions 
in HbA1c and weight compared to placebo [42]. In the 
present study, according to the method of our previous 
report [39], empagliflozin was administered in the diet 
(containing 0.03% empagliflozin), because the diet con-
taining such a concentration of empagliflozin is shown 
Table 3 Non-fasting blood sugar, HbA1c, insulin, 
and  lipids in  SHRcp fed empagliflozin-containing diet or 
control diet for 10 weeks
Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing 
empagliflozin. Values are mean ± SEM. Statistical analysis was performed by 
unpaired Student’s t test
* P < 0.01 versus control
Control (n = 11–12) SGLT2 (n = 12)
Non‑fasting blood sugar (mg/
dl)
227 ± 17 140 ± 6*
HbA1c (%) 1.30 ± 0.03 1.12 ± 0.02*
Insulin (ng/mL) 103.6 ± 12.2 22.4 ± 2.4*
Total cholesterol (mg/dL) 206 ± 6 207 ± 9
Triglyceride (mg/dL) 591 ± 51 812 ± 39*
Free fatty acid (mmol/L) 0.46 ± 0.03 0.48 ± 0.02
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to be suitable for investigating the long-term effect of 
empagliflozin in diabetic animals. As expected, empa-
gliflozin significantly increased urinary glucose excre-
tion in prediabetic MS rats throughout 10  weeks of the 
treatment, being associated with the slight but signifi-
cant reduction in HbA1c and the significant decrease in 
plasma insulin levels. The reduction of plasma insulin 
levels by empagliflozin in SHRcp seems to be secondary 
to the normalization of blood glucose levels but not the 
direct effect on insulin secretion. Furthermore, greater 
urinary sodium excretion, smaller sodium balance, and 
smaller water balance in empagliflozin than in control 
were observed within the initial one week of the treat-











































































































































Fig. 7 Effect of 7 weeks of empagliflozin treatment of systolic BP and diastolic BP (a), heart rate (b), locomotor activity (c), and circadian rhythm 
during 24 h (12‑h dark period and 12‑h light period) of systolic BP (d), diastolic BP (e), heart rate (f), and locomotor activity (g) of SHRcp as estimated 
by telemetry system. Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing empagliflozin; UGE urinary glucose excretion; NS not 
significant. SBP systolic blood pressure; DBP diastolic blood pressure; HR heart rate. Values are mean ± SEM n = 5 in control, n = 6 in SGLT2. In a, b 
and c, statistical analysis was performed by two‑factor ANOVA with repeated measures. In d, e, f and g, statistical analysis was performed by two‑
factor ANOVA followed by post hoc Tukey’s multiple comparisons test
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empagliflozin in prediabetic SHRcp. On the other hand, 
later than one week of the treatment, urinary sodium 
excretion and urinary sodium or water balance were sim-
ilar between empagliflozin and control groups of SHRcp. 
The lack of difference between the groups in urinary 
sodium or water balance during prolonged treatments is 
likely to be accounted for by the action of other renal Na 
transporters, although further study is required to eluci-
date this point.
Effects of empagliflozin on blood pressure
Convincing evidence [11, 21, 26] indicates that SGLT2 
inhibitors including empagliflozin significantly reduce 
BP in type 2 diabetic patients and natriuretic action 
of SGLT2 inhibitors is postulated to participate in BP 
reduction. However, there is no available information 
concerning the effect of SGLT2 inhibition on BP in pre-
diabetic MS. In our previous paper, we have shown that 
Table 4 Main effects and  interaction P values for  drug 
and  time analyzed by  two-way ANOVA in  Experiment III 
(experiment using radiotelemetry system)
SBP systolic blood pressure; DBP diastolic blood pressure; LF low frequency; sBRG 
spontaneous baroreceptor reflex gain; HF high frequency; PI pulse interval; NS 
not significant
Parameters (figure number) Ptime Pdrug Pinteraction
24 h‑averaged SBP (Fig. 7a) <0.01 NS NS
24 h‑averaged DBP (Fig. 7a) <0.01 NS <0.01
24 h‑averaged heart rate (Fig. 7b) <0.01 NS NS
24 h‑averaged locomotor activity (Fig. 7c) <0.01 NS NS
Hourly SBP (Fig. 7d) <0.01 NS NS
Hourly DBP (Fig. 7e) <0.01 NS NS
Hourly heart rate (Fig. 7f ) <0.01 NS NS
Hourly locomotor activity (Fig. 7g) <0.01 P < 0.05 NS
LF‑SBP (Fig. 8a) <0.01 NS NS
sBRG (Fig. 8b) <0.01 NS NS
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Fig. 8 Effect of 7 weeks of empagliflozin treatment on circadian rhythm of LF‑SBP (a), sBRG (b), and LF/HF ratio of PI (c) during 24 h (12‑h dark 
period and 12‑h light period) of SHRcp as estimated by telemetry system. Control SHRcp fed control diet; SGLT2, SHRcp fed control diet containing 
empagliflozin; UGE urinary glucose excretion; NS not significant. PI pulse interval. Values are mean ± SEM n = 5 in control, n = 6 in SGLT2. Statistical 
analysis was performed by two‑factor ANOVA with repeated measures
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SHRcp exhibits higher blood pressure and the increased 
sympathetic activity compared to control WKY rats [27]. 
Therefore, SHRcp is a suitable model to investigate the 
effect of empagliflozin on blood pressure or sympathetic 
activity in prediabetic MS rats. In the present study, by 
using radiotelemetry system, we continuously moni-
tored the long-term effect of empagliflozin on direct BP, 
HR, baroreflex function, and autonomic activity in pre-
diabetic MS rats. Our continuous direct monitoring indi-
cated that empagliflozin treatment did not significantly 
alter systolic or diastolic BP and HR or their circadian 
rhythm in SHRcp. Furthermore, empagliflozin did not 
affect autonomic nerve activity or baroreceptor function 
in SHRcp, as evidenced by no alteration of LF-SBP, sBRG, 
or LF/HF ration of PI. Our results on BP of prediabetic 
MS rats differ from clinical findings observed in type 2 
diabetic patients. However, it should be noted that in the 
present study, SHRcp were fed normal salt diet but not 
high-salt diet. Furthermore, osmotic diuresis caused by 
glycosuria appears to be much less in prediabetic SHRcp 
than in diabetic animals, because SHRcp exhibited much 
less blood glucose levels than diabetic animal models, 
and therefore, the extent of glycosuria induced by empa-
gliflozin in SHRcp was slight.
Effects of empagliflozin on cardiac injury
The potential effect of SGLT2 inhibition on cardiac dis-
ease is paid the most attention, since empagliflozin is 
demonstrated to reduce cardiovascular events and heart 
failure hospitalization in type 2 diabetic patients [12–14, 
38]. To address this issue, we investigated the effect of 
empagliflozin on cardiac injury in SHRcp, since we have 
previously shown that SHRcp displays cardiac hyper-
trophy, cardiac fibrosis, cardiac inflammation, and car-
diac oxidative stress more than control WKY rat [27]. 
In the present study, of note, empagliflozin significantly 
reduced cardiac myocyte hypertrophy and interstitial 
fibrosis in SHRcp, despite no significant lowering of BP 
by empagliflozin. Furthermore, empagliflozin signifi-
cantly reduced cardiac oxidative stress and inflammation 
but did not change cardiac triglyceride contents and did 
not reduce plasma lipids in SHRcp. Taken together with 
the fact that oxidative stress and inflammation play a piv-
otal role in the pathogenesis of cardiac hypertrophy and 
remodeling [43–45], our present observations show that 
the amelioration of cardiac hypertrophy and fibrosis by 
empagliflozin in SHRcp was attributed to the attenua-
tion of oxidative stress and inflammation but not to BP. 
However, at present, cardioprotection of empagliflozin 
observed in this work seems unlikely to be mediated by 
its direct cardiac action, because SGLT2 receptor does 
not exist in cardiac tissue. Further study is required to 
elucidate the precise mechanism responsible for cardio-
protection by empagliflozin in prediabetic MS.
Effects of empagliflozin on obesity
Accumulating studies provide the solid evidence that 
long-term SGLT2 inhibition causes the reduction of 
body weight in type 2 diabetic patients [11, 24]. How-
ever, the underlying mechanism remains to be clari-
fied. Therefore, in the present study, we examined the 
effect of empagliflozin on body weight and adipose tis-
sues in SHRcp. We found that long-term SGLT2 inhibi-
tion significantly decreased body weight in prediabetic 
MS rats and significantly reduced subcutaneous fat 
tissue weight but not visceral fat tissue weight. There-
fore, the decrease in body weight of prediabetic MS 
rats subjected to empagliflozin treatment seems to be 
attributed to the decrease in subcutaneous fat tissue 
rather than visceral fat. However, of note, empagliflo-
zin treatment significantly increased the proportion of 
smaller adipocytes while decreased the proportion of 
larger adipocyte in visceral (epididymal) adipose tis-
sue, indicating the amelioration of visceral adipocyte 
hypertrophy by empagliflozin. Moreover, this ameliora-
tion of visceral adipocyte hypertrophy by empagliflozin 
was accompanied by the reduction of oxidative stress 
(lipid oxidation). Our present observations provided the 
first evidence that SGLT2 inhibition with empagliflozin 
caused the reduction in visceral adipocyte hypertrophy 
and the reduction in oxidative stress in prediabetic MS 
rats. On the other hand, unlike visceral (epididymal) 
fat, subcutaneous fat oxidative stress was not altered by 
empagliflozin. Thus, the effect of empagliflozin seems 
to be different between visceral and subcutaneous fat 
tissues. Furthermore, unexpectedly, serum triglyceride 
levels were higher in empagliflozin group than in con-
trol group. The increased triglyceride levels in empa-
gliflozin group may be attributed to the increased food 
intake in this group, although further study is required 
to elucidate this point.
In conclusion, we first examined the detailed effect of 
SGLT2 inhibition on prediabetic MS rats. We obtained 
the evidence that empagliflozin ameliorated cardiac 
hypertrophy and fibrosis in prediabetic MS rats, through 
attenuation of oxidative stress and inflammation, inde-
pendently of BP. Furthermore, empagliflozin treatment 
provided the reduction in visceral adipocyte hypertrophy 
and the attenuation of visceral adipocyte oxidative stress 
in prediabetic MS rats. Thus, our present work highlights 
SGLT2 inhibition as a novel therapeutic strategy for MS 
with prediabetic stage.
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